—
C+
C+ The full Closelook — membership. Open the C+ overview

Kiniksa Pharmaceuticals Ltd (KNSA) — Quality & forensics

As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

56 /100 composite · 7 modules · general weight set

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

19.93 Altman Z-Score

Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

5/8 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

-2.11 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.

Continue: the KNSA chart & overview · the earnings record

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Kiniksa Pharmaceuticals Ltd's Closelook quality reading?

The composite reads 56/100 across 7 modules, as of 2026-09-18: valuation 19, quality 58, growth 71, balance sheet 91, cash quality 28, capital allocation 21, momentum 92. Closelook scores are research diary readings, not ratings or investment advice.

What is Kiniksa Pharmaceuticals Ltd's Altman Z-Score?

19.93, which sits in the safe zone (above 2.99) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Kiniksa Pharmaceuticals Ltd's Piotroski F-Score?

5 of 8, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does Kiniksa Pharmaceuticals Ltd's Beneish M-Score indicate?

-2.11 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.